Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Other Accumulated Expenses came in at $583000.0 in Q1 2026, down 50.09% YoY from $1.2 million in Q1 2025, and down 94.31% on a QoQ basis from $10.2 million in Q4 2025.
Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Other Accumulated Expenses data on file, last reported at $583000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 50.09% year-over-year to $583000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $583000.0 (down 50.09% YoY) and the FY2026 annual result came in at $583000.0, down 50.09% from the prior year.
- Other Accumulated Expenses fell to $583000.0 in Q1 2026, from $10.2 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $76.3 million in Q1 2023 to a low of $583000.0 in Q1 2026.
- A 5-year average of $31.8 million and a median of $27.5 million in 2024 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 602.7% — and 2025, when it sank 97.38%.
- Tracing ROIV's Other Accumulated Expenses over 5 years: stood at $14.3 million in 2022, then surged by 204.87% to $43.6 million in 2023, then increased by 22.55% to $53.5 million in 2024, then slumped by 80.84% to $10.2 million in 2025, then plunged by 94.31% to $583000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $583000.0 (Q1 2026), $10.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.21 Mn |
| Mar 31, 2026 | 583,000.00 |
| Dec 31, 2025 | 10.24 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 49.80 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 53.47 Mn |
| Sep 30, 2024 | 56.30 Mn |
| Jun 30, 2024 | 27.53 Mn |
| Mar 31, 2024 | 31.82 Mn |
| Dec 31, 2023 | 43.63 Mn |
| Sep 30, 2023 | 72.55 Mn |
| Jun 30, 2023 | 19.89 Mn |
| Mar 31, 2023 | 76.28 Mn |
| Dec 31, 2022 | 14.31 Mn |
| Sep 30, 2022 | 66.92 Mn |
| Jun 30, 2022 | 4.08 Mn |
| Mar 31, 2022 | 10.86 Mn |
| Dec 31, 2021 | 12.44 Mn |
| Sep 30, 2021 | 10.66 Mn |